Health Press Release – Newsletter for November 9, 2010

Gen-Probe Launches the ELUCIGENE(TM) KRAS.BRAF Kit to Detect Genetic Mutations That Help Determine Colorectal Cancer Treatment

First Single-Tube Assay to Simultaneously Detect Seven KRAS and One BRAF Mutations

MANCHESTER, England, November 8, 2010 – Gen-Probe Incorporated (Nasdaq: GPRO) has launched in Europe the
ELUCIGENE(TM) KRAS.BRAF kit, a highly sensitive, single-tube assay designed
for the simultaneous quantitative detection of seven common KRAS mutations
and the V600E BRAF mutation. The CE-marked assay provides valuable
information regarding mutation …. Read the original article  : here.

Mederi Therapeutics Announces Receipt of CE Mark for its Second Generation Secca(R) and Stretta(R) Systems

GREENWICH, Connecticut, November 8, 2010 – Mederi Therapeutics Inc announced today that it has received a CE Mark
authorizing the European distribution and use of Mederi's second generation
of the Stretta and Secca Systems. The Stretta System is for treatment of
gastric reflux disease, commonly known as GERD, and the Secca System is for
treatment of bowel control … Read : Mederi Therapeutics Announces Receipt of CE Mark for its Second Generation Secca(R) and Stretta(R) Systems.

Elsevier’s Scival(R) Spotlight(TM) Country Maps Provide a National Perspective of Interdisciplinary Research

AMSTERDAM, November 8, 2010 – Elsevier, the world-leading publisher of scientific, technical and
medical information products and services, today announced the availability
of SciVal Spotlight country maps (www.info.scival.com). The country
maps are a new option for academic and governmental decision makers seeking
to understand national research strengths against the increasingly
interdisciplinary backdrop of global research. They are an extension …. Original source  : Elsevier's Scival(R) Spotlight(TM) Country Maps Provide a National Perspective of Interdisciplinary Research.

Scottish Medicines Consortium Approves Zebinix – Once Daily Anti-Epileptic Treatment

LONDON, November 8, 2010 – Zebinix(R) (eslicarbazepine acetate), a treatment for epilepsy, has been
accepted for restricted use in Scotland after a decision by The Scottish
Medicines Consortium (SMC).[1] Following the new clinical and cost
effectiveness decision, Zebinix can now be used as an add-on (adjunctive)
therapy in adults with partial-onset seizures, with or without secondary
generalisation (where the …. Source  : Gaea News Network.

Abbott Presents Data Exploring Relationship of Physical Function to Inflammation and Structural Damage in RA

ABBOTT PARK, Illinois, November 8, 2010 – Today, Abbott (NYSE: ABT) presents results from a pooled analysis of two
pivotal HUMIRA(R) (adalimumab) studies, which look at patients with early and
long-standing moderate to severe rheumatoid arthritis (RA), at the American
College of Rheumatology meeting in Atlanta.

The study looked at inflammation and structural damage … Read this article on Gaea Times at : Abbott Presents Data Exploring Relationship of Physical Function to Inflammation and Structural Damage in RA.

Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa

ABBOTT PARK, Illinois, November 8, 2010 – Abbott (NYSE: ABT) and the Clinton Health Access Initiative (CHAI) have
joined forces to provide HIV testing to infants in all countries working in
partnership with the CHAI. A key focus of this cooperation will be
sub-Saharan Africa, which the World Health Organization estimates to account
for 90 percent of global …. Source article on Gaea Times at  : Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa.

Sanofi-aventis Sends Letter to Genzyme Seeking Clarification on Potential Board Actions

PARIS, November 8, 2010 – Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that it has
sent a letter to Genzyme Corporation (Nasdaq: GENZ) requesting that Genzyme
clarify its position on a number of potential Board actions raised in
Genzyme's Schedule 14D-9.

Sanofi-aventis' letter also notes that it is encouraged by Genzyme's
decision to "probe … Read the original article on Gaea Times at : Sanofi-aventis Sends Letter to Genzyme Seeking Clarification on Potential Board Actions.